New Delhi metallo-β-lactamase-producing Acinetobacter isolates among late-onset VAP patients: multidrug-resistant
Asmaa M Elbrolosy1, Azza Z Labeeb1, Dina M Hassan2
1Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt, asmaaelbrolosy@yahoo.com.
Background:
Acinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP).
Purpose:
The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) (blaNDM-1)-producing Acinetobacter spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of blaNDM-1-producing Acinetobacter infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients.
Materials And Methods:
Sixty-four Acinetobacter isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for blaNDM-1 MβL detection. Acinetobacter isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of blaNDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed.
Results:
Out of 64 Acinetobacter isolates, 42 (65.6%) proved to be blaNDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively. Acinetobacter isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with blaNDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients.
Conclusion:
A worldwide spread of Acinetobacter spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of blaNDM-1-producing Acinetobacter isolates among late-onset VAP patients.
Insights
New Delhi metallo-β-lactamase (MβL) producing Acinetobacter is a significant threat in ventilator-associated pneumonia (VAP). This study found a high prevalence of blaNDM-1 in VAP patients, with risk factors including prolonged ventilation and prior antibiotic exposure.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Critical Care Medicine
Background:
- Acinetobacter species are increasingly implicated in late-onset ventilator-associated pneumonia (VAP).
- The emergence of carbapenem resistance in Acinetobacter poses a significant clinical challenge.
Purpose of the Study:
- Determine the prevalence of New Delhi metallo-β-lactamase (MβL) (blaNDM-1)-producing Acinetobacter in VAP patients.
- Investigate risk factors for acquiring blaNDM-1-producing Acinetobacter infections.
- Correlate antimicrobial resistance patterns with therapeutic efficacy and clinical outcomes.
Main Methods:
- Collected 64 Acinetobacter isolates from VAP patients.
- Performed antimicrobial susceptibility testing, modified Hodge test (MHT), and combined disk tests (CDT) for MβL detection.
- Utilized PCR to confirm the presence of the blaNDM-1 gene and analyzed risk factors and treatment outcomes.
Main Results:
- 42 (65.6%) of 64 Acinetobacter isolates were blaNDM-1 positive.
- Combined disk tests showed higher sensitivity (92.86%) and specificity (83.33%) for MβL detection compared to MHT.
- Colistin exhibited high susceptibility (85.7%); combined carbapenem-colistin therapy improved clinical response.
- Mortality was 46.8%, with 64.3% of deaths linked to blaNDM-1 positive isolates.
- Prolonged mechanical ventilation, longer hospital/ICU stays, and prior antibiotic use were key risk factors for carbapenem resistance.
Conclusions:
- The high prevalence of blaNDM-1-producing Acinetobacter in VAP patients highlights a significant global health threat.
- Effective antimicrobial stewardship and infection control are crucial to combat the spread of carbapenem-resistant Acinetobacter.
Related Concept Videos
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Predicting Reaction Outcomes
Resistivity
Resistance
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Equivalent Resistance


